Tech Company Financing Transactions
Ultragenyx Pharmaceutical Funding Round
F-Prime Capital participated in a $15.1 million funding round for Ultragenyx Pharmaceutical. The round was recorded on 9/30/2012.
Transaction Overview
Company Name
Announced On
9/30/2012
Transaction Type
Venture Equity
Amount
$15,100,000
Round
Undisclosed
Investors
F-Prime Capital (Benjamin Auspitz)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
60 Leveroni Ct.
Novato, CA 94949
USA
Novato, CA 94949
USA
Phone
Website
Email Address
Overview
Ultragenyx (NASDAQ: RARE) is focused on developing therapeutics for rare diseases. The company will build on management's experience in choosing and developing products with clear mechanisms of action in untreated rare diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Emil Kakkis
Chief Financial Officer
Shalini Sharp
Chief Operating Officer
John Pinion
VP - Bus. Development
Thomas Kassberg
Browse more venture capital transactions:
Prev: 9/30/2012: EAT Club venture capital transaction
Next: 9/30/2012: NKT Therapeutics venture capital transaction
Share this article
Where The Data Comes From
We do our best to record all VC transactions involving tech companies. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs